Editas Medicine, Inc. (EDIT) stock
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine, Inc. grew revenue 7.4% to $49.83M over the twelve months to Sep 30, 2026. Free cash flow was -$110.46M. At the latest close the market valued the company at $365.52M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $365.52M
- P/E ratio
- –
- Price to sales
- 7.34
- Price to book
- 4.32
- Dividend yield
- –
- Free cash flow yield
- -30.22%
Fundamentals
- Revenue
- $49.83M
- Net income
- -$72.23M
- EPS, diluted
- -$0.62
- Free cash flow
- -$110.46M
- Book value per share
- $0.55
- Diluted shares
- 154M
Trading
- Next earnings
- Mar 8, 2027 (estimated, before the open)
- Previous close
- $2.50
- Open
- $2.51
- Day's range
- $2.36 – $2.52
- Volume
- 1,980,323
- Average volume (20 days)
- 2,133,805
- Index membership
- Russell 2000, Russell 3000 (since Aug 2025)
- Beta (5 years)
- 2.19
- 52-week range
- $1.66 – $3.94
- RSI (14 days)
- 43.0
- Volatility (1 year)
- 82.6%
- Relative volume
- 0.81×
- WACC
- 15.0%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EDIT | S&P 500 | Difference | EDIT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.9% | -2.4% | −15.5 pts | ||
| 3 months | -19.3% | -1.2% | −18.2 pts | ||
| Year to date | +16.1% | +12.3% | +3.8 pts | ||
| 1 year | -10.5% | +12.4% | −23.0 pts | ||
| 3 years | -69.0% | +78.8% | −147.8 pts | -32.3% | +21.4% |
| 5 years | -93.8% | +75.2% | −168.9 pts | -42.6% | +11.9% |
| 10 years | -85.4% | +311.1% | −396.5 pts | -17.5% | +15.2% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Editas Medicine filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- Update
- Update
About Editas Medicine
Biological Products, (No Diagnostic Substances)
The company is a biotechnology firm that develops genomic medicines utilizing CRISPR-based gene editing technology, including Cas9 and Cas12a systems. Its core scientific approach focuses on in vivo functional upregulation, which edits non-coding regulatory DNA sequences to increase normal gene and protein expression. The firm's lead experimental product candidate is EDIT-401, designed to treat hyperlipidemia and heterozygous familial hypercholesterolemia by targeting the low-density lipoprotein receptor gene. The organization also researches in vivo treatments for hemoglobinopathies such as sickle cell disease and transfusion-dependent beta thalassemia, alongside a lipid nanoparticle delivery platform for liver and extrahepatic tissues. It serves patients with genetic conditions and collaborates with biopharmaceutical partners by out-licensing its intellectual property for cancer and autoimmune disease therapies.
Company profile, executives and historyEditas Medicine stock: common questions
What is Editas Medicine's stock price?
EDIT closed at $2.38 on Nov 11, 2026, down 4.99% on the day. Over the past 52 weeks it traded between $1.66 and $3.94.
What is Editas Medicine's market cap?
Editas Medicine was worth $365.52M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is EDIT's P/E ratio?
Editas Medicine lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.62), so it has no meaningful P/E ratio.
How much revenue does Editas Medicine make?
Editas Medicine reported revenue of $49.83M for the twelve months to Sep 30, 2026, up 7.4% from a year earlier.
Does Editas Medicine pay a dividend?
No. Editas Medicine has not paid a cash dividend over the last twelve months.
When does Editas Medicine report earnings next?
Editas Medicine is expected to report Q4 FY2026 results on Mar 8, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has EDIT stock performed over the past year?
Including dividends, EDIT returned -10.5% over the past year, against +12.4% for the S&P 500.
How many EDIT shares are sold short?
39M shares were sold short at the latest FINRA report, 25.33% of the float, or 17.6 days of average trading volume.
Who are Editas Medicine's competitors?
Companies most similar to Editas Medicine by business, industry and size include DTIL, CRSP, SGMOQ, MGX, FDMT.
See a number that looks wrong?